Allogeneic HSCT · 10 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Fludarabine and TBI for haploidentical transplant, then allo HSCT Variant #01 Partial | — | R 16 505 | — | — | — | ~1 | ~R 16 505 indirect | — |
Busulfan and Cyclophosphamide Variant #01 | — | R 6 777 | — | — | — | ~1 | ~R 6 777 indirect | — |
Etoposide and TBI Variant #01 | — | R 6 770 | — | — | — | ~1 | ~R 6 770 indirect | — |
BEAM Variant #01 Partial | — | R 4 346 | — | — | — | ~1 | ~R 4 346 indirect | — |
Cyclophosphamide and TBI Variant #01 | — | R 1 176 | — | — | ~90.0 mo | ~1 | ~R 1 176 PFS proxy · indirect | 2 |
BFR Partial | — | — | — | — | — | — | — | — |
BuCyTBI Partial | — | — | — | — | — | — | — | — |
Busulfan and Fludarabine Partial | — | — | — | — | — | — | — | — |
Fludarabine, Busulfan, Cyclophosphamide Partial | — | — | — | — | — | — | — | — |
Busulfan, Cyclophosphamide, Decitabine, G-CSF Partial | — | — | — | — | — | — | — | — |
10 of 10 regimens shown